<DOC>
	<DOC>NCT00612573</DOC>
	<brief_summary>Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and the absolute change from baseline in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. Additionally, the absolute change from baseline in non-inflammatory and total lesions of the active study medication to placebo will be evaluated.</brief_summary>
	<brief_title>Treatment of Moderate to Severe Facial Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Must be between 12 and 45 years of age. Has a diagnosis of moderate to severe facial acne vulgaris with no more than two nodules on the face Is allergic to tetracyclineclass antibiotics or to any ingredient in the study medication. Has a history of pseudomembranous colitis or antibioticassociated colitis. Has a history of hepatitis or liver damage or renal impairment.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>